(888) 31-NDASA info@NDASA.com
  • Facebook
  • X
  • Instagram
  • RSS
  • Facebook
  • X
  • Instagram
  • RSS
  • NDASA
  • NDASA University
  • Member Login
0 Items
NDASA
  • About
    • Leadership
  • Training
    • NDASA University
      • My Courses
    • NDASA University Partner Program
    • Webinars
      • Webinar Library
    • Accreditation
    • Mentorship
  • Get involved
    • Committees
      • International Council
      • Community Outreach
    • Become a Trainer
    • State Affiliate Caucus
    • Our Federal PAC
    • Board of Directors
  • Join us
    • Member Benefits
    • Sponsorships & Advertising
    • Accreditation
    • Preferred Provider
  • News
    • Resources
  • Events
    • 2026 Conference and Trade Show
    • 2025 Conference Highlights
    • Regional Training
  • Shop
  • Support
    • Sponsorships & Advertising
    • NDASA Foundation
  • Help
Select Page

U.S. DOT Medical Marijuana Notice

by NDASA | Apr 23, 2021 | For Drug Testing Industry Professionals, Marijuana & CBD, Resources

“Medical Review Officers will not verify a drug test as negative based upon information that a physician recommended that the employee use “medical marijuana.” Please note that marijuana remains a drug listed in Schedule I of the Controlled Substances Act. It remains...
How the Collector can make the MRO’s job easier and ensure a smooth screening process

How the Collector can make the MRO’s job easier and ensure a smooth screening process

by Guest Contributer | Mar 9, 2021 | Drug & Alcohol Testing, Feature

By Dr. William D. Brooks, American Association of Medical Review Officers (AAMRO), Founding Member, Past V.P., Trainer, Advisory Board Member GAC & Education Committee NDASA, OStG Today’s litigious marketplace requires all participants in a drug testing program to...

Search this site

Stay in touch

  • Follow
  • Follow
  • Follow
  • Follow

Give to NDASA

Invest in safe and drug-free communities and workplaces and support NDASA.
Give now

Latest News & Updates

  • Apr 14, 2025C/TPA best-practice recomendations for ensuring client compliance
  • Apr 14, 2025Building a Defensible Breath Alcohol Testing Program
  • Apr 14, 202510 Reasons Why A Drug Testing Policy Needs to Be Updated Regularly
  • Apr 14, 2025From Invisible to Influential: How AI Can Elevate Credibility and Drive Sales in the Drug Testing Industry
  • Apr 14, 2025Leaders on the frontline: Tackling substance use with empathy and insight

Topics We Track

  • Advocacy (14)
  • Business Development (7)
  • Committee Reports (1)
  • DOT (19)
  • Drug & Alcohol Testing (54)
  • Drug Legislation (17)
  • Feature (119)
  • FMCSA (7)
  • For Drug Testing Industry Professionals (24)
  • For Employers and Workplace Safety & Wellness Professionals (18)
  • Industry News (31)
  • Marijuana & CBD (24)
  • Member Benefits (4)
  • Membership (6)
  • MROs (3)
  • NDASA Conference (18)
  • NDASA Guidance (4)
  • NDASA News (4)
  • Newsletter Only (9)
  • Opioids (3)
  • Oral Fluid Testing (2)
  • Partners (1)
  • Resources (36)
  • Substance Use (5)
  • Substance Use/Addiction (10)
  • The Voice (6)
  • Training (4)
  • Uncategorized (25)
  • Workplace Safety (17)

  • C/TPA best-practice recomendations for ensuring client compliance
  • Building a Defensible Breath Alcohol Testing Program
  • 10 Reasons Why A Drug Testing Policy Needs to Be Updated Regularly
  • From Invisible to Influential: How AI Can Elevate Credibility and Drive Sales in the Drug Testing Industry
  • Leaders on the frontline: Tackling substance use with empathy and insight

Legal Documents

  • Articles of Incorporation
  • Exemption Letter
  • IRS Designation Letter

NDASA Bylaws

  • Bylaws

Careers

Visit our job board

NDASA Policies

  • Privacy Policy
  • Security Policy
  • Refund Policy
  • Shipping Policy

Join the Newsletter

Proud Member of

Thank you to our sponsors

 

© 2023 National Drug and Alcohol Screening Association • All Rights Reserved • Web Powered by Media Salad